carbapenems has been researched along with Central Nervous System Infection in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, J; Liu, Y; Wang, H; Wu, G; Xu, X | 1 |
| Hu, F; Li, S; Qin, X; Wang, C; Wang, J; Wang, M; Zhang, Y; Zhao, X | 1 |
2 other study(ies) available for carbapenems and Central Nervous System Infection
| Article | Year |
|---|---|
Intravenous plus intraventricular tigecycline-amikacin therapy for the treatment of carbapenem-resistant Klebsiella pneumoniae ventriculitis: A case report.
Topics: Amikacin; Anti-Bacterial Agents; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Central Nervous System Infections; Cerebral Ventriculitis; Encephalitis; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Middle Aged; Tigecycline | 2022 |
Ceftazidime-avibactam-based combination therapy for hospital-acquired central nervous system infections caused by carbapenem-resistant Klebsiella pneumoniae.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Ceftazidime; Central Nervous System Infections; Drug Combinations; Hospitals; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Retrospective Studies | 2023 |